      Document 0058
 DOCN  DRG0058
 UNIQUE IDENTIFIER        DRG-0189
 NAME OF SUBSTANCE        Tumor Necrosis Factor soluble
                          receptor-immunoadhesin complex [NIAID
                          93-I-206]
 SYNONYMS                 rhu TNFR:Fc [NIAID 93-I-206]
 SYNONYMS                 TNFR:Fc [NIAID 93-I-206]
 PROTOCOL ID NUMBERS      NIAID 93-I-206
 SECONDARY SOURCE ID      DRG
 PHARMACOLOGICAL ACTION   MODE OF ACTION: TNF alpha is produced in
                          humans as part of an immune response. Some
                          individuals with HIV have been shown to have
                          high levels of TNF alpha. In the laboratory
                          setting, TNF alpha has been shown to enhance
                          HIV replication. TNF alpha may also be
                          associated with the nutritional depletion of
                          HIV infection. The effects of blocking TNF
                          alpha with rhu TNFR:Fc, a TNF blocking agent,
                          are being studied. [NIAID 93-I-206] [AmFAR Tx
                          Dir 1995;7(4)]
 DISEASES STUDIED/TREATED Inhibition of tumor necrosis factor
                          production in HIV infection [AmFAR Tx Dir
                          1995;7(4)]
 CLASSIFICATION CODE      Immunomodulator [AmFAR Tx Dir 1995;7(4)]
 ADVERSE EFFECTS          Adverse effects include skin rash and chest
                          tightness (single IV dose). [AmFAR Tx Dir
                          1995;7(4)]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: A TNF blocking agent [NIAID
                          93-I-206]
 SUBSTANCE DELIVERY DATA  Subcutaneous. [NIAID 93-I-206]
 REFERENCES               Agostini C, Zambello R, Trentin L, Cerutti A,
                          Enthammer C, Facco M, Milani A, Sancetta R,
                          Garbisa S, Semenzato G. Expression of TNF
                          receptors by T cells and membrane TNF-alpha
                          by alveolar macrophages suggests a role for
                          TNF-alpha in the regulation of the local
                          immune responses in the lung of HIV-1
                          infected patients. J Immunol. 1995 Mar
                          15;154(6):2928-38.
 REFERENCES               Wilt SG, Milward E, Zhou JM, Nagasato K,
                          Patton H, Rusten R, Griffin DE, O'Connor M,
                          Dubois-Dalcq M. In vitro evidence for a dual
                          role of tumor necrosis factor-alpha in human
                          immunodeficiency virus type 1 encephalopathy
                          [see comments]. Ann Neurol. 1995
                          Mar;37(3):381-94.
 REFERENCES               Puccioni-Sohler M, Rieckmann P, Kitze B,
                          Lange P, Albrecht M, Felgenhauer K. A soluble
                          form of tumour necrosis factor receptor in
                          cerebrospinal fluid and serum of
                          HTLV-1-associated myelopathy and other
                          neurological diseases. J Neurol. 1995
                          Mar;242(4):239-42.
 REFERENCES               Zangerle R, Fuchs D, Sarcletti M, Gallati H,
                          Reibnegger G, Wachter H, Dierich MP, Most J.
                          Increased concentrations of soluble tumor
                          necrosis factor receptor 75 but not of
                          soluble intercellular adhesion molecule-1 are
                          associated with the decline of CD4+
                          lymphocytes in HIV infection. Clin Immunol
                          Immunopathol. 1994 Sep;72(3):328-34.
 REFERENCES               Zangerle R, Gallati H, Sarcletti M, Wachter
                          H, Fuchs D. Tumor necrosis factor alpha and
                          soluble tumor necrosis factor receptors in
                          individuals with human immunodeficiency virus
                          infection. Immunol Lett. 1994
                          Jul;41(2-3):229-34.
 REFERENCES               Godfried MH, van der Poll T, Weverling GJ,
                          Mulder JW, Jansen J, van Deventer SJ,
                          Sauerwien HP. Soluble receptors for tumor
                          necrosis factor as predictors of progression
                          to AIDS in asymptomatic human
                          immunodeficiency virus type 1 infection. J
                          Infect Dis. 1994 Apr;169(4):739-45.
 REFERENCES               Aukrust P, Liabakk NB, Muller F, Lien E,
                          Espevik T, Froland SS. Serum levels of tumor
                          necrosis factor-alpha (TNF alpha) and soluble
                          TNF receptors in human immunodeficiency virus
                          type 1 infection--correlations to clinical,
                          immunologic, and virologic parameters
                          [published erratum appears in J Infect Dis
                          1994 May;169(5):1186-7]. J Infec Dis. 1994
                          Feb;169(2):420-4.
 REFERENCES               Beutler B, Grau GE. Tumor necrosis factor in
                          the pathogenesis of infectious diseases. Crit
                          Care Med. 1993 Oct;21(10 Suppl):S423-35.
 ENTRY MONTH              9309
 LAST REVISION DATE       960417
 

SOURCE: National Library of Medicine, Bethesda, MD.  Distributed by AEGIS.
